SUPRIYA
Micro CapSupriya Lifescience Limited
Pharma
Supriya Lifescience is a global leader in Anti-histamines, Anti-Allergic, Vitamins, Anti-Asthmatics & Anesthetics, offering 40+ APIs. It operates in 120+ countries, with 82% of FY26 revenue from exports. The company has a 35,000 Sq.mts manufacturing facility with 932 KLPD reactor capacity and strong backward integration (76% of FY26 revenue).
One read, four checks
75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.
Mixed fundamentals, management trust is supportive, price trend is neutral, and recent execution is consistent.
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
low confidence · 0/0 claims checked
Timing lens: price trend and sector relative strength.
Rolling lens: recent quarterly delivery, not the latest single-result score.
Quarter ended 31 Mar 2026
Good · 72/100Rev +51% YoY · PAT +48% YoY · +34% QoQ · margin compression
| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹277 Cr | +50.5% | +34.5% |
| EBITDA | ₹98 Cr | +44.1% | +36.1% |
| Operating margin | 35.0% | -200 bps | +0 bps |
| PAT | ₹74 Cr | +48.0% | +48.0% |
| PAT margin | 26.7% | -46 bps | +244 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Where growth can come from, and what can break the case
Supriya Lifescience reported robust Q4 FY26 performance with revenue up 50% YoY to INR 2,765.3 Mn, EBITDA up 44% YoY to INR 976.2 Mn, and PAT up 47% YoY to INR 742.3 Mn. For FY26, revenue grew 19% YoY to INR 8,278.7 Mn, but EBITDA and PAT margins contracted by 192 bps and 173 bps YoY, respectively.
The company delivered strong top-line growth in Q4 and FY26, driven by new product launches and export market penetration. However, margin contraction in both periods raises questions about cost management or product mix shifts. Future growth relies on successful R&D, capacity expansion, and deeper market penetration, particularly in regulated markets.
Revenue Contribution – By Region (Q4 FY26)
Latest issuer-disclosed distribution across 5 reported categories.
New Product Launches
Key Cardio Vascular, ADHD, and Liquid Anesthetic products launched in FY26. Planning ~2 launches each in Anesthetic and ADHD for FY27.
Market Expansion
Expanded API customer base across Japan, EU, and US. Secured agreements in South Asia and initiated supplies for ROW markets.
Backward Integration
76% of FY26 revenue from backward integrated products, enabling supply security and cost-competitive structure.
CMO/CDMO Opportunities
Evaluating exclusive manufacturing rights in liquid inhalation products, GLP-1 portfolio development, and novel combination product discussions.
New Vitamin Product Block
Successfully commissioned, contributing to enhanced production capabilities.
Debottlenecking & New Block
Civil work initiated for debottlenecking across all production blocks. A new 'F' block will be added at Lote for capacity expansion.
Finished Dosage Lines
Five finished dosage manufacturing lines are operational, with a new nasal line planned to strengthen capabilities.
Strategic Land Acquisitions
Acquired 12,551 sq.mt. adjacent to existing facility, 24,646 sq.mt. for backward integration, and 80,000 sq.mt. at Isambe.
Diversified Geographic Presence
Presence in 120+ countries, with 82% of FY26 revenue from exports, indicating low dependence on a specific geography.
Backward Integration
76% of FY26 revenue from backward integrated products ensures steady raw material supply and protection against market fluctuations.
Strong Regulatory Compliance
Achieved 4th USFDA approval for Lote Facility in 2026, along with 21 USDMFs and 11 CEPs, supporting global market access.
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Q4 results show strong sequential momentum (QoQ) in addition to significant YoY growth, indicating recent business acceleration. Full-year (YoY) provides a broader view of annual performance and market position.
Export Revenue Contribution
FY26 revenue from exports was 82% of total revenue.
New Product Launches
A key Cardio Vascular product launched in Q3FY26, ADHD product in Q4FY26, and Liquid Anesthetic commercialized. Planning ~2 launches each in Anesthetic and ADHD for FY27.
Regulatory Approvals
Received 4th USFDA approval for Lote Facility in 2026. ANVISA Approval Granted in 2024. Holds 21 USDMFs and 11 CEPs.
API/CDMO Mix
76% of FY26 revenue derived from backward integrated products. Evaluating CMO/CDMO opportunities for liquid inhalation products and GLP-1 portfolio.
API R&D Expansion
Ambernath API R&D facility fully commissioned, aiming to develop 3-4 APIs annually with a focus on innovation and IP creation.
Finished Dosage Pipeline
30 products under development across various dosage forms, with five exhibits completed and a novel Semaglutide tablet formulation developed.
Global Market Penetration
Regulatory filings in EU and US underway, with plans to file six dossiers in the EU this financial year to enable long-term contracts.
Capacity Enhancement
New vitamin product block commissioned, debottlenecking initiated, and a new production block (F block) planned at Lote.
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| EBITDA Margin | 35.5% (FY26) | Improvement from current levels, given the YoY contraction in both Q4 and FY26. |
| New Product Launches & Scale-up | Key Cardio Vascular, ADHD, Liquid Anesthetic launched in FY26. | Successful launch and commercial scale-up of ~2 Anesthetic and ~2 ADHD products planned for FY27. |
| Export Revenue Contribution | 82% (FY26) | Sustained high export contribution and successful penetration into new regulated geographies (EU, US, Japan). |
| Capacity Expansion & Utilization | New vitamin block commissioned, debottlenecking underway, new F block planned. | Timely commissioning and ramp-up of new capacities, along with specific utilization rates. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trend score and candlestick chart
55NeutralSMA20 +16.7% / mo
Technical chart
SUPRIYAweekly · 1Y+39.6%Technical trend read
NeutralTrend is undirectional — long-term trend unclear. RSI 65.
- SMA20 rising (~14.3% over last month) — short-term momentum positive.
- RSI(14) at 65 — sideways, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- 11% off 52W high · 77% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Valuation, score drivers, trust methodology, financials, and peers
Use these sections after reviewing the decision summary, latest result, thesis, management accountability, and technical timing above.
Fundamental score breakdown
FAIR VALUEWhy this score?
Top U-Score contributors and drags from the latest stored fundamentals.
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 17.8%.
- Balance sheet contributes 11/15 to the score.
Main drags
- Valuation is weaker at 4/30; verify the latest quarterly trend.
- Cash flow is weaker at 4/10; verify the latest quarterly trend.
- Growth is weaker at 13/25; verify the latest quarterly trend.
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Score history
12 stored score snapshots. Latest stored move: +1 points.
Factor attribution
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
High Trust: Claim history is still being built. It ranks around the 100th percentile of the scored universe and 100th percentile within Pharma. No major sub-score weakness stands out.
High Trust Lite: Promoter holding is 68.3%.
Management behaviour ranks as unusually reliable. Still verify valuation and cycle risk.
overall median 67 · Pharma: 100th pctile, median 70 · Micro: 100th pctile, median 71
0 documents indexed, but claim history is not strong enough yet.
0 claims extracted · No contradicted claim yet
How to read this Trust Score
High Trust · low confidenceRead Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Trust positives
- ▸Promoter holding is 68.3%.
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 0.2%.
- ▸5 years of positive FCF.
Trust risks
- ▸No major Trust Lite risk flags.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Intrinsic value
Fundamentals
Valuation
- P/E
- 35.30
- P/B
- 6.17
- EV/EBITDA
- 22.99
- Market Cap
- 7397.00Cr
Profitability
- ROE
- 19.10%
- ROCE
- 25.10%
- ROA
- 15.40%
- Dividend Y
- 0.11%
Growth (CAGR)
- Revenue 5Y
- 16.00%
- EPS 5Y
- 11.00%
- Revenue 3Y
- 22.00%
- EPS 3Y
- 33.00%
Balance Sheet
- Debt/Equity
- 0.00
- Interest Coverage
- 147.00×
- Altman Z
- 8.86
- Book Value
- 149.00
Cash Flow
- FCF Yield
- 0.18%
- FCF Positive Y
- 5/5
- OCF
- 165.00 Cr
- EPS TTM
- 25.98
Shareholding
- Promoter Hold
- 68.30%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 69%
Financial History
Updated 9/6/2026
Revenue
₹ CrNet Profit
₹ CrReturn on Equity
%Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.